ADVERTISEMENT
Search

Emergency Action is Necessary to Provide Payment for Pharmacist Prescribing of Paxlovid

APhA needs your assistance to ensure you can effectively care for you patients. Reach out to your Member of Congress and Senators and ask them to take immediate action to provide adequate, appropriate, and fair payment for pharmacist consultations and services for prescribing Paxlovid.

Act now  

APhA’s Learning Library

We’re excited to announce the launch of the new APhA Learning Library! This new platform will make it easier than ever for you to get the education you need. Read about some key highlights of our new system.

Learn more  

Community Pharmacy Workplace Summit

APhA is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that result in improved workplaces, well-being, and ability to meet ethical obligations to patient safety.

Learn more  

Featured Education

Upcoming Events

Practice Resources

Tools and resources to support your practice

Access Now  

image-6
 

Latest from APhA

View CEO Blog

Ilisa Bernstein's Letter to the FDA Regarding Pharmacists Prescribing Oral COVID-19 Treatments

A letter from Interim CEO Ilisa Bernstein, PharmD, JD, FAPhA, to Dr. Robert Califf, Commissioner of the Food and Drug Administration (FDA), on the importance of pharmacists being allowed to prescribe oral COVID-19 treatments.

RSS

Provider status alert: Nevada pharmacists can now bill Medicaid for certain services

CARSON CITY, NV, and WASHINGTON, DC—The Nevada Pharmacy Alliance (NPA) and the American Pharmacists Association (APhA) are proud to announce that Nevada pharmacists can now bill the state’s Medicaid program for certain health care services.

RSS

Pharmacy news

View all news

Study highlights urgency of removing access to OUD meds

Researchers at NYU Grossman School of Medicine say 86.6% of people living with opioid use disorder (OUD) in the United States are not receiving medications proven to reduce opioid overdoses, including methadone, buprenorphine, and extended-release naltrexone. Their study, published in International Journal of Drug Policy, looked at differences between new estimates of OUD prevalence and the use of medications for OUD (MOUD) at the national and state levels from 2010 to 2019.

Analysis finds novel drugs will get record prices in 2022

Drug companies are asking for lofty prices for new medications coming to market, a Reuters analysis finds, often while disclosing little pricing information about the treatments.

RSS